|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
WHO004387333 |
003 |
DE-627 |
005 |
20230425183421.0 |
007 |
cr uuu---uuuuu |
008 |
210507s2022 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)WHO004387333
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2014-001931-36-DE
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)CLEE011E2301
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)2014-001931-36-HU
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a Study of Efficacy and Safety of LEE011 in Premenopausal Women With Advanced Breast Cancer
|b A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer - Monaleesa-7
|
264 |
|
1 |
|c 2022
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 28-10-2014, Last updated: 2022-11-24
|
650 |
|
4 |
|a Medical Condition: premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer MedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 3
|
650 |
|
4 |
|a Recruitment Status: Not yet recruiting
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2022) vom: 08. Aug.
|
773 |
1 |
8 |
|g year:2022
|g day:08
|g month:08
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001931-36
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
912 |
|
|
|a SSG-OLC-PHA
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2022
|b 08
|c 08
|